Assessing regression of cervical precancerous lesions and risk factors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the histopathological regression of severe cervical precancerous lesions (CIN 2 and CIN 3) and the normalization of HPV tests and cytology findings in patients treated conservatively or through conization. Patients will undergo colposcopic evaluations every four months, with biopsies performed to assess regression or persistence of lesions. The study will also identify predictive factors associated with regression and propose a model to predict the likelihood of lesion regression based on the collected data.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. squamocolumnar junction fully visualized
2. bioptically verified CIN 2 or CIN 3
3. age ≥ 18 years
4. age ≤ 40 years
5. informed consent

Exclusion Criteria:

1. squamocolumnar junction not fully visualized
2. suspicion on glandular lesion
3. suspicion on invasive cancer
4. personal history of CIN 2, 3 or cerv. cancer
5. gravidity
6. HIV positivity
7. immunosuppression
8. impossible photographic documentation

Where it's running

• General University Hospital
  Prague, Czechia Recruiting

Study contacts

• Study coordinator: Lukas Dostalek
• Email: lukas.dostalek@vfn.cz
• Phone: +420224967451

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Urine HPV testing for cervical cancer screening in HIV-infected women in South Africa

  This study tests whether using urine samples to check for HPV can help screen for cervical cancer in women living with HIV in South Africa.

  Recruiting UNC Lineberger Comprehensive Cancer Center · Westdene, Johannesburg · NCT05413798

• Assessing immune response after HPV vaccination in women

  This study is testing how long the immune protection lasts in Chinese women aged 9-45 after they complete the full HPV vaccination schedule.

  Recruiting at 2 sites Shanghai Bovax Biotechnology Co., Ltd. · Yangchun, Guangdong and 1 other locations · NCT05371353

• Evaluating a 9-valent HPV vaccine in healthy Chinese women

  This study is testing a new 9-valent HPV vaccine in healthy Chinese women aged 20-45 to see how well it works and if it's safe for preventing HPV-related cancers.

  Recruiting Phase 3 Shanghai Bovax Biotechnology Co., Ltd. · Liuzhou, Guangxi · NCT04422366

• Can people collect their own vaginal sample for HPV testing as well as clinician collection for comparison?

  This study tests whether individuals can correctly use a self-collection device to gather a vaginal sample for high-risk HPV screening and whether the self-collected sample agrees with clinician-collected samples.

  Recruiting at 11 sites Mel Mont Medical · Phoenix, Arizona and 10 other locations · NCT07758140

• Low-thermal Argon Plasma Devitalization for CIN2 Treatment

  This study tests whether a low-thermal argon plasma treatment can heal CIN2 on the cervix better than a sham procedure or active surveillance in women aged 18–40.

  Recruiting University Hospital Tuebingen · Tübingen, Baden-Wurttemberg · NCT07730645

• Two-probe thermal ablation for cervical precancer in WLWH in South Africa

  This study tests whether using two probes for thermal ablation is safer or more effective than one probe for treating cervical precancer in women living with HIV in South Africa.

  Recruiting Fred Hutchinson Cancer Center · Durban · NCT07645378

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.